GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

1st line

IRB #2377
A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

No Trials Currently Available

IRB 11974
SOLACE: A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization with Drug-Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally-Advanced Hepatocellular Carcinoma

IRB #15816
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)

IRB #11746
I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients with Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy with Sorafenib

Cholangiocarcinoma

Prior Therapy

2nd line

IRB #15077
9785-CL-3021: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma

IRB# #15077

1st line

1st or 2nd Line

Key

- Open for Enrollment
- In Development
- Enrollment on Hold